Asian Penny Stocks To Watch In September 2026

The Asian markets have been navigating through a period of volatility, influenced by global economic shifts and regional developments. Amid these fluctuations, investors are increasingly drawn to the potential of penny stocks, a term that may seem outdated but still holds significant investment relevance. These smaller or newer companies can offer surprising value when supported by strong financials, presenting opportunities for growth and stability in an otherwise unpredictable market landscape.

Let's review some notable picks from our screened stocks.

RiseSun Real Estate DevelopmentLtd (SZSE:002146)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: RiseSun Real Estate Development Co., Ltd operates in the development and sale of real estate properties in China, with a market capitalization of approximately CN¥5.48 billion.

Operations: The company's revenue from its operations in China amounts to CN¥18.71 billion.

Market Cap: CN¥5.48B

RiseSun Real Estate Development Co., Ltd, with a market cap of CN¥5.48 billion, faces financial challenges as it remains unprofitable and has seen earnings decline by 14.2% annually over the past five years. Despite having short-term assets of CN¥107.7 billion that cover both short- and long-term liabilities, the company's high net debt to equity ratio of 469% raises concerns about its financial stability. Recent earnings showed a significant revenue drop to CN¥6.17 billion from CN¥14.18 billion year-on-year but reduced net losses indicate some operational improvements. Shareholders recently approved a debt restructuring proposal, which may impact future financial strategy.

• Take a closer look at RiseSun Real Estate DevelopmentLtd's potential here in our financial health report.
• Evaluate RiseSun Real Estate DevelopmentLtd's historical performance by accessing our past performance report.

HARBIN GLORIA PHARMACEUTICALS (SZSE:002437)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: HARBIN GLORIA PHARMACEUTICALS Co., LTD, along with its subsidiaries, focuses on the research, development, production, and sale of pharmaceutical products in China and internationally, with a market cap of CN¥8.34 billion.

Operations: The company generates revenue primarily from Chemical Medicine, amounting to CN¥1.86 billion, and Traditional Chinese Medicine, contributing CN¥177 million.

Market Cap: CN¥8.34B

HARBIN GLORIA PHARMACEUTICALS, with a market cap of CN¥8.34 billion, demonstrates financial strength through consistent earnings growth, with a 65.8% increase over the past year surpassing industry trends. The company's price-to-earnings ratio of 20.8x suggests it is undervalued relative to the broader Chinese market average of 41x. It maintains robust cash flow and has successfully reduced its debt-to-equity ratio from 80.3% to 3.5% over five years, indicating improved financial health. Despite stable weekly volatility at 12%, share price fluctuations remain higher than most Chinese stocks, which may concern risk-averse investors seeking stability in penny stock investments.

• Get an in-depth perspective on HARBIN GLORIA PHARMACEUTICALS' performance by reading our balance sheet health report here.
• Learn about HARBIN GLORIA PHARMACEUTICALS' historical performance here.

Huafon Microfibre (Shanghai) (SZSE:300180)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Huafon Microfibre (Shanghai) Co., Ltd. develops, manufactures, and sells microfiber materials both in China and internationally, with a market cap of CN¥8.21 billion.

Operations: Huafon Microfibre (Shanghai) Co., Ltd. does not report specific revenue segments.

Market Cap: CN¥8.21B

Huafon Microfibre (Shanghai) Co., Ltd., with a market cap of CN¥8.21 billion, shows mixed financial performance. The company reported half-year revenue of CN¥1.97 billion, up from the previous year, but net income decreased to CN¥33.81 million from CN¥75.68 million due to lower profit margins and significant one-off gains impacting results. Despite this, Huafon maintains a strong balance sheet with short-term assets exceeding liabilities and satisfactory debt levels with a net debt-to-equity ratio of 3.6%. The management team is experienced with an average tenure of 3.9 years, contributing to operational stability amidst earnings volatility challenges.

• Navigate through the intricacies of Huafon Microfibre (Shanghai) with our comprehensive balance sheet health report here.
• Examine Huafon Microfibre (Shanghai)'s past performance report to understand how it has performed in prior years.

Seize The Opportunity

• Click here to access our complete index of 1,041 Asian Penny Stocks.
• Curious About Other Options? The latest GPUs need a type of rare earth metal called Dysprosium and there are only 36 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com